23Na-MRI for Breast Cancer Diagnosis and Treatment Monitoring: A Scoping Review

23Na-MRI在乳腺癌诊断和治疗监测中的应用:范围界定综述

阅读:4

Abstract

(1) Background: Variations in intracellular and extracellular sodium levels have been hypothesized to serve as biomarkers for tumour characterization and therapeutic response. While previous research has explored the feasibility of 23Na-MRI, a comprehensive review of its clinical utility in breast cancer is lacking. This scoping review aims to synthesize existing literature on the potential role of 23Na-MRI in breast cancer diagnosis and treatment monitoring. (2) Methods: This review included English-language studies reporting on quantitative applications of 23Na-MRI in breast cancer. Systematic searches were conducted across PubMed, Emcare, Embase, Scopus, Google Scholar, Cochrane Library, and Medline. (3) Results: Seven primary studies met the inclusion criteria, highlighting the ability of 23Na-MRI to differentiate between malignant and benign breast lesions based on elevated total sodium concentration (TSC) in tumour tissues. 23Na-MRI also showed potential in early prediction of treatment response, with significant reductions in TSC observed in responders. However, the studies varied widely in their protocols, use of phantoms, field strengths, and contrast agent application, limiting inter-study comparability. (4) Conclusion: 23Na-MRI holds promise as a complementary imaging modality for breast cancer diagnosis and treatment monitoring. However, standardization of imaging protocols and technical optimization are essential before it can be translated into clinical practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。